Phase II trials have shown encouraging activity with ipilimumab plus fotemustine and ipilimumab plus nivolumab in melanoma brain metastases. We report the primary analysis and four-year follow-up of the NIBIT-M2 study, the first phase III trial comparing these regimens to fotemustine in melanoma patients with brain metastases.
Primary analysis and four-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases
Quaglino, Pietro;Marchetti, Paolo;Amato, Giovanni;
2021-01-01
Abstract
Phase II trials have shown encouraging activity with ipilimumab plus fotemustine and ipilimumab plus nivolumab in melanoma brain metastases. We report the primary analysis and four-year follow-up of the NIBIT-M2 study, the first phase III trial comparing these regimens to fotemustine in melanoma patients with brain metastases.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
